The first and only clinically validated circulating TTMV® DNA blood test that aids in the detection of HPV-driven cancer.

A highly accurate, reliable blood test.

NavDx is the first and only clinically validated circulating tumor-tissue–modified HPV (TTMV®) DNA blood test that aids in the detection of HPV-driven cancer.

 

NavDx uses proprietary technology to quantify fragments of circulating TTMV HPV DNA, a unique HPV-driven cancer biomarker that cancer cells shed into the blood. This highly accurate blood test reliably uncovers the presence of HPV+ head and neck cancer across the care continuum.¹˒²

This innovative and accessible blood test for HPV+ cancer helps inform clinical decisions, enabling physicians to intervene earlier, which may result in improved outcomes.¹

References: 1. Chera BS, Kumar S, Shen C, et al. Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer.
J Clin Oncol. 2020;38(10):1050-1058. 2. Chera BS, Kumar S, Beaty BT, et al. Rapid clearance profile of plasma circulating tumor HPV type 16 DNA during chemoradiothera-py correlates with disease control in HPV-associated oropharyngeal cancer. Clin Cancer Res. 2019;25(15):4682-4690. 3. Head and neck cancers. Version 3.2021. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) 2021; https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. 4. Data on file. Naveris Inc.

Get Started with NavDx